Trial reportDrug design, development and therapy2026
Dose-Response Relationship of Single Intravenous Remimazolam on Bispectral Index and Cardiorespiratory Effects.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Bispectral Index (BIS) is a standardized, continuous measure of sedation depth. Studies have shown that remimazolam can induce a decrease in BIS, but the dose-response relationship between single-dose remimazolam and BIS remains unclear. Purpose: This study aimed to explore the correlation between single intravenous doses of remimazolam and BIS, and to observe its effects on respiration and circulation. Patients and Methods: This was a prospective, randomized, double-blind, dose-finding study. One hundred patients scheduled for elective surgery under general anesthesia were randomly assigned to five groups and received intravenous remimazolam at 0.2, 0.3, 0.4, 0.5, or 0.6 mg/kg before anesthesia induction. BIS values at each time point, minimum BIS (BISmin), vital signs, adverse events, and interventions were recorded. Probit regression was used to calculate the ED Results: BIS values decreased more significantly with increasing remimazolam doses, with a plateau effect observed above 0.4 mg/kg. The BISmin values for each group were 60.6 ± 10.4, 58.4 ± 9.2, 58.1 ± 6.2, 55.6 ± 7.9, and 55.0 ± 6.4, respectively. Using the BIS ≤ 60 threshold, the ED Conclusion: A dose-dependent relationship exists between single-dose remimazolam and BIS, with good respiratory and circulatory safety in the 0.2-0.6 mg/kg range and a plateau effect above 0.4 mg/kg. The extremely wide confidence interval for the ED
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.